Sodium-Glucose Cotransporter-2 Inhibitor in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
This cohort study evaluated adoption rates of sodium-glucose cotransporter-2 inhibitors at US hospitals for patients with heart failure and mildly reduced or preserved left ventribular ejection fraction.